Scalper1 News
RBC Capital Markets upgraded generic drugmaker Akorn (AKRX) to outperform from sector perform Monday, sending the stock up 1.5% in morning trading on the stock market today, near 36. Analyst Randall Stanicky cited a good environment for U.S. generic drugs in general, with an accelerating approval rate and strong pricing trends. “AKRX’s pipeline sets up well for FDA action with 44% of its 93 ANDAs filed in 2012 or earlier (at least 24 months old) Scalper1 News
Scalper1 News